What’s next for CAR T cell therapy? What’s the best way to develop combination therapies for multi-modal efficacy?

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our first ever Immuno Discussion Group addressing ‘Understanding The Tumour Microenvironment With Advanced Technologies’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

The activation of GPR65 on immune cells by the acidic tumour microenvironment and the resultant immunosuppression may be one of the principal reasons many cancers do not respond to current T Cell checkpoint therapies. Chief Executive Officer Stuart Hughes delves into some of Pathios Therapeutics recent developments in macrophage conditioning and its promise to enable a successful anti-tumour immune response.

Hosted by Robert Power, Manager, Product Management at Personalis, Inc

Russell LaMontagne, Co-Founder and Chief Executive Officer, Boston Immune Technologies and Therapeutics

Ruth Seelige, Senior Scientist, Pfizer

Russell LaMontagne, Chief Executive Officer, Boston Immune Technologies & Therapeutics Inc